GM CSF Mouse

GM CSF Mouse

  • Name
  • Description
  • Cat#
  • Pricings
  • Quantity
  • GM CSF Mouse

  • Granulocyte Macrophage-Colony Stimulating Factor Mouse Recombinant
  • CYT-222
  • Shipped at Room temp.

Catalogue number



CSF-2, MGI-1GM, GM-CSF, Pluripoietin-alpha, CSF2, GMCSF


GMCSF is a cytokine that controls the production, differentiation, and function of granulocytes and macrophages. The active form of the protein is found extracellularly as a homodimer. This gene has been localized to a cluster of related genes at chromosome region 5q31, which is known to be associated with interstitial deletions in the 5q- syndrome and acute myelogenous leukemia. Other genes in the cluster include those encoding interleukins 4, 5, and 13.
GM-CSF stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes.


Granulocyte Macrophage Colony Stimulating Factor Mouse Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 125 amino acids and having a molecular mass of 14285.35 Dalton.
GM-CSF Mouse is purified by proprietary chromatographic techniques.


Escherichia Coli.

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.


GM-CSF Mouse was lyophilized with no additives.


It is recommended to reconstitute the lyophilized Granulocyte Macrophage Colony Stimulating Factor in sterile 20mM AcOH (acetic Acid) not less than 100µg/ml, which can then be further diluted to other aqueous solutions.


Lyophilized Granulocyte Macrophage Colony Stimulating Factor although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution GM-CSF should be stored at 4°C between 2-7 days and for future use below -18°C.
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please prevent freeze-thaw cycles.


Greater than 98.0% as determined by(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.

Amino acid sequence

The sequence of the first five N-terminal amino acids was determined and was found to be Met-Ala-Pro-Thr-Arg.

Biological Activity

The ED50 as determined by the dose-dependant stimulation of the proliferation of murine FDC-P1 cell line is < 0.2 ng/ml, corresponding to a Specific Activity of 5,000,000 IU/mg.

Protein content

GM-CSF quantitation was carried out by two independent methods
1. UV spectroscopy at 280 nm using the absorbency value of 0.765 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).

2. Analysis by RP-HPLC, using a calibrated solution of GM-CSF as a Reference Standard.

Safety Data Sheet


1.Title:Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery.
Publication: Mol Ther. 2005 Dec;12(6):1197-205. Epub 2005 Aug 22. PMID: 16112909
Link: GM CSF prospec publication
Applications: The Mouse GM-CSF used for 2 purposes:
1. As an adjuvant for DNA vaccine which included seven plasmids encoding nine HIV-1 proteins. The mice were injected with the DNA vaccine together with recombinant mouse GM-CSF. 2. Used in Elisa.

2.Title: Neospora caninum: cloning and expression of a gene coding for cytokine-inducing profilin. 
Publication: Exp Parasitol. 2010 Aug;125(4):357-62. Epub 2010 Mar 6. PMID: 20211619
Link: GM CSF Mouse prospec publication
Applications: Used for immunoblotting

3.Title: Intranasal Granulocyte-Macrophage Colony-Stimulating Factor Reduces the Aspergillus Burden in an Immunosuppressed Murine Model of Pulmonary Aspergillosis.
Publication: Antimicrob Agents Chemother. 2008 February; 52(2): 716–718.
Published online 2007 November 5
Link: GM CSF Protein prospec publication
Applications: GM-CSF as tested a therapeutic potential in a murine model of pulmonary aspergillosis. In summary, this pilot study indicates that GM-CSF administered intranasally may be a novel therapeutic approach for the prevention or treatment of pulmonary fungal infections and may augment the efficacies of antifungal agents.
GM-CSF was given intranasal.

Title: Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma
Publication: The Journal of Immunology February 1, 2009 vol. 182 no. 3 1667-1673
GM CSF Mouse Protein prospec publication


5.Title:Pre-clinical Evaluation of a CEA DNA Prime/protein Boost Vaccination Strategy Against Colorectal Cancer.
Publication:Article first published online: 21 JUN 2007 DOI:10.1111/j.1365-3083.2007.01945.x

Scandinavian Journal of Immunology Volume 66, Issue 1, pages 43–51, July 2007
Link:Granulocyte Macrophage-Colony Stimulating Factor prospec publication

6.Title:Intranasal Granulocyte-Macrophage Colony-Stimulating Factor Reduces the Aspergillus Burden in an Immunosuppressed Murine Model of Pulmonary Aspergillosis.
Publication: First published November 2007, doi: 10.1128/?AAC.00760-07 Antimicrob. Agents Chemother. February 2008 vol. 52 no. 2 716-718
Link:Granulocyte Macrophage-Colony Stimulating Factor Mouse publication


7. Title: O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
 Clinical & Experimental Immunology 143.1 (2006): 139-149.
Link: GMCSF Protein prospec publication


8. Title: Novel Functions of Herbal Medicines in DendriticCells: Role of Amomi Semen in Tumor Immunity
Publications:  Microbiology and immunology 51.11 (2007): 1121-1133.
Link: GM-CSF prospec publication


9. Title: The Herbal Medicine Compound Falcarindiol from Notopterygii Rhizoma Suppresses Dendritic Cell Maturation
Publication:  Journal of Pharmacology and Experimental Therapeutics 333.3 (2010): 954-960.
Link: CSF-2 Protein prospec publication


ProSpec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Back to Top